GLP-1 Drugs Show Promise in Reducing Obesity-Related Cancer Risks

New study highlights significant reduction in risk for multiple cancers among Type 2 diabetes patients using GLP-1 medications.

Patients using GLP-1 drugs had a lower risk of developing 10 out of 13 obesity-related cancers compared to those on insulin.
The study analyzed electronic health records of over 1.6 million Type 2 diabetes patients from 2005 to 2018.
GLP-1 medications like Ozempic, Wegovy, and Victoza were linked to decreased risks of colorectal, pancreatic, and esophageal cancers.
No significant risk reduction was noted for thyroid or postmenopausal breast cancer.
Further research is needed to confirm these findings and explore the drugs' long-term effects.